| Revenue growth | Revenue +32% YoY to INR 2,710 Mn. |
|---|---|
| Margins | EBITDA margin 27% vs 29%; PAT margin 9% vs 12%. |
| Demand visibility | Tests +85% YoY; patients +35%; retail revenue +35%. |
Growth
Revenue +32% YoY and +15% QoQ; EBITDA +20% YoY. H1 FY27 revenue INR 5,065 Mn (+27%), H1 PAT INR 411 Mn (-8%).
Outlook
No explicit numeric guidance given. Strategic push: PET CT entry, Apulki oncology/cardiac investment.
Risks
Channel partner fees 19% of revenue (8% LY); finance costs up 89% YoY; receivables up 61% since March.
Last quarter's promises, checked
Delivered
- Margin to improve QoQ (Q1 EBITDA 25%) → Q2 EBITDA 27% (= BEAT)
Partly delivered
- Retail 10-15% of FY27 revenue → Q2 retail 9% (= PARTIAL, FY open)
- Margins back to double digits by FY-end (metric unspecified) → Q2 EBITDA 27%, PAT 9% (= PARTIAL)
- Rajasthan dip to normalise as revenue scales → Q2 EBITDA 27% vs 29% LY, Rajasthan still cited (= PARTIAL)
Missed
- Karnataka/HP/Maharashtra cash by Q2 → receivables up 61% since March, no collection shown (= MISS)
Investor Presentation filed with BSE, NSE: KRSNAA. Summary written with AI assistance from the document.
Krsnaa Diagnostics Ltd: key numbers
- Share price
- ₹467.60
- Market cap
- ₹1,517 Cr
- Revenue (annual)
- ₹772.8 Cr
- Net profit (annual)
- ₹101.4 Cr
- P/E (TTM)
- 15.6×Sector 52.8×
- Promoter holding
- 27.11%+0.00% QoQ
- FII holding
- 3.84%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Krsnaa Diagnostics Ltd
All →Krsnaa Diagnostics Results Update
Krsnaa Diagnostics reported record Q2 revenue of Rs 2,710 million, up 32% year on year. H1 PAT fell to Rs 411 million on Rajasthan project costs.
Krsnaa Diagnostics Q2 FY27 Results: Net Profit ₹24.6 Cr, Up 2.9% YoY
Krsnaa Diagnostics Ltd reported revenue from operations of ₹271 Cr (+31.6% YoY) and net profit of ₹24.6 Cr (+2.9% YoY) for Q2 FY27.
- Key figure
- Net profit ₹24.6 Cr · +2.9% YoY
Krsnaa Diagnostics Board Meeting Date
Krsnaa Diagnostics intimated that its board will meet on November 2, 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. No financial figures are disclosed in this notice.
Krsnaa Diagnostics Partnership
Krsnaa Diagnostics has formed a strategic AI collaboration with AZmed to integrate AI radiology solutions for enhanced operational efficiency and scalable diagnostic reporting.
- From
- AZmed
Krsnaa Diagnostics Other Announcement
Krsnaa Diagnostics Ltd submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the period ended September 30, 2026.
Krsnaa Diagnostics Convertible Warrants
Krsnaa Diagnostics has allotted 16,21,000 convertible warrants to 2 investors at a price of Rs. 566 per warrant.
- Value
- ₹91.75 Cr